About Careers MedBlog Contact us

Around 6,000 Healthcare Workers Will be Part of Ebola Vaccine Trial in Sierra Leone

by Dr. Trupti Shirole on April 15, 2015 at 9:53 AM
Font : A-A+

Around 6,000 Healthcare Workers Will be Part of Ebola Vaccine Trial in Sierra Leone

The deadliest Ebola outbreak in history began in West Africa in late 2013 and has killed more than 10,000 people, mainly in Liberia, Sierra Leone and Guinea. Thousands of healthcare workers in areas of Sierra Leone who are grappling with Ebola will now begin receiving an experimental vaccine, rVSV-ZEBOV, against the often deadly virus. The vaccine candidate has been developed by the Public Health Agency of Canada and licensed to NewLink Genetics and Merck pharmaceuticals.

The US Centers for Disease Control and Prevention (CDC) said, "It will be given to 6,000 healthcare workers and other front line personnel in the fight against Ebola over the coming months. The vaccine trial, known as STRIVE (Sierra Leone Trial to Introduce a Vaccine against Ebola), is being conducted in Freetown, the Western Area Rural district and certain chiefdoms in Bombali, Port Loko, and Tonkolili districts. These study locations were selected because they have been heavily affected by the Ebola outbreak in the past few months."


So far, the vaccine has already been studied in more than 800 people as part of ongoing vaccine trials in Africa, Canada, Europe, and the United States. Reportedly, the vaccine appears to be safe and those who take it show an immune response to Ebola. However, it remains unclear if the vaccine can prevent Ebola infection, and if it does, how much protection it may provide. Therefore people who take it must still follow all precautionary measures to avoid Ebola infection, such as covering their skin, mouth, nose and eyes and not coming in direct contact with the bodily fluids of those who are ill.

Anne Schuchat, director of CDC's National Center for Immunization and Respiratory Diseases, said, "The vaccine cannot cause Ebola virus disease but can potentially stimulate an immune response to protect against the disease. We don't know whether this vaccine will be the Ebola prevention tool we're all eager for, but we hope that what we learn from STRIVE will help us save lives during this and future Ebola outbreaks."

Source: Medindia


Recommended Reading

Latest Tropical Disease News

Oral Cholera Vaccine Launched in India by Pharma Giants
Mumbai's TechInvention Lifecare and South Korean Eubiologics team up to introduce oral cholera vaccine in India after successful phase III clinical trial.
Evolving Threat of Dengue Virus in India
Scientists have found that the dengue virus has become more severe in India, highlighting the urgent need for vaccines that target the strains found in the country.
 Watch Out for Acute Kidney Disease as a Complication of Malaria
It is important to consider malarial infection in cases of acute kidney injury in someone with a travel history from endemic areas to improve treatment outcomes.
India's Malaria Vaccine Gets the Green Light for First Time in Ghana
Ghana approves the use of the University of Oxford's malaria vaccine, produced by the Serum Institute of India (SII), becoming the first country to adopt the new vaccine.
 Deadly Dengue Virus Hijacks Mosquito Saliva to Spread Sickness
The dengue virus combines molecules from its RNA with mosquito saliva to foil the human immune system and spread dengue fever and related diseases.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Around 6,000 Healthcare Workers Will be Part of Ebola Vaccine Trial in Sierra Leone Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests